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Abstract
Background: The first case of 2009 pandemic influenza A (H1N1) virus infection was documented in our Hospital
on 10th August 2009.
Metdods and findings: Real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) testing was used to
confirm the diagnosis. All patients were treated with oseltamivir from the first day of hospitalization. Upon
admission 12/44 had local patchy shadowing in their chest x-ray and additionally antibiotic regimen was added to
these patients as pneumonia was suspected based on clinical evidence. In total 44 patients were hospitalized
15/44 had asthma, 6/44 COPD, 5/44 leukemia. Lung function was evaluated with forced vital capacity, forced
expiratory volume in 1 sec and diffused carbon monoxide upon discharge and every 3 months, until 6 months of
observation was completed after discharge. The purpose of this retrospective cohort study was to evaluate
whether influenza A (H1N1) had an impact on the respiratory capacity of the infected patients.
Conclusions: An improvement of pulmonary function tests was observed between the first two measurements,
implicating an inflammatory pathogenesis of influenza A (H1N1) to the respiratory tract. This inflammation was not
associated with the severity or clinical outcome of the patients. All patients had a mild clinical course and their
respiratory capacity was stable between the second and third measurement, suggesting that the duration of
respiratory inflammation was two months. Early treatment with antiviral agents and vaccination represent the
mainstay of management.
Introduction
The first human infections with the new influenza
A (H1N1) virus were confirmed in April 2009 in Amer-
ica, but the infection had been rapidly spreading around
the world and in June 2009 World Health Organization
(WHO) declared a pandemic [1-5]. WHO had advised
countries in the northern hemisphere to prepare for a
second wave of pandemic spread [6]. To date, almost all
countries in the world have confirmed a second wave of
H1N1 virus [7,8]. For this reason a working group of
WHO member states agreed on a pandemic influenza
preparedness framework [9]. The reason for creating
this framework began with the need for real time virolo-
gical data exchange among laboratories in different
countries upon a pandemic outbreak [10,11]. The H1N1
virus has resulted from a triple recombination contain-
ing genes from human, avian, and swine influenza virus
[12,13]. The incidence, clinical characteristics and fac-
tors affecting the patients outcome of the first wave
have been well described in previous published studies
[14-17]. However, while the numbers of positive H1N1
patients were lower, the hospitalisation rates were higher
in comparison to the numbers and rates of 2009. In
addition, the proportion of hospitalised cases admitted
to intensive care units (ICU) was higher in 2010. The
reason for these differences are not yet completely clear.
There has been no obvious change in the severity of
pandemic influenza A (H1N1) 2009 disease thresholds
for hospital and ICU admission [8]. Three possible
explanations were given. First, a new pandemic influenza
A (H1N1) genetic variant predominated in the winter
2010 influenza season [7]. The Influenza A (H1N1)
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This mutation was associated with severe clinical out-
come in comparison to the usual influenza A (H1N1)
2009 strain [7,18,19]. Secondly, resistance to oseltamivir
developing from the first wave reached a peak in the
2010 pandemic [20,21]. Thirdly, it has been reported
that this year’s seasonal vaccine effectiveness was mod-
erate, suggesting an insufficient protective effect against
the second wave of influenza A (H1N1) [22-27].
In this retrospective study,w ee v a l u a t e dt h er e s p i r a -
tory capacity of 44 patients admitted to the Unit of
Infectious Diseases (UID) of our hospital from 10
th
August 2009 to 15
th November 2010. These were fol-
lowed with Forced Vital Capacity (FVC), Forced Expira-
tory Volume in 1 sec (FEV1) and Carbon Monoxide
Diffusing Capacity (DLCO) for a period of six months
after their discharge. The rationale for the study
was published data that H1N1 presents with hypoxemia
and acute respiratory distress syndrome (ARDS)
[14-17,28,29]. In addition, we examined the clinical
characteristics of these patients.
Patients and methods
Methods of establishing H1N1 and precaution measures
Pharyngeal or nasopharyngeal swabs were taken upon
admission in accordance with the protocol from the
U.S. Centers for Disease Control and Prevention, as
recommended by WHO and the average time between
obtaining the samples and testing was 8-48 hours. The
laboratory of the University Hospital of Alexandroupolis
is a reference center for infectious diseases for more
than 350.000 residents and one of the most important
reference centers in Nothern Greece. Confirmed case
was defined by a positive result of a real-time reverse-
transcriptase-polymerase-chain-reaction (RT-PCR) [30].
The pandemic (H1N1) 2009 influenza virus is
t h o u g h tt os p r e a df r o mp e r s o nt op e r s o ni nt h es a m e
way as seasonal influenza, where transmission occurs
predominantly through droplets produced from cough-
ing or sneezing. Indirect transmission may also occur
through self-inoculation after contact with surfaces or
objects contaminated with the virus from infected per-
sons. The incubation period for pandemic (H1N1)
2009 influenza virus is understood to be approximately
four days (range: 1-7 days). The period of communic-
ability is estimated to be seven days in uncomplicated
cases; however, it may be lo n g e ri nc h i l d r e n( u pt o1 0
days) and other individuals in whom symptoms and
virus shedding may persist (i.e. immuno-compromised
and severely ill). Consistent with seasonal influenza,
transmission of the pandemic (H1N1) 2009 influenza
virus is most likely during the initial days of infection
when cases are typically symptomatic and have higher
viral loads [31].
The following isolation precautions were recom-
mended for healthcare personnel who are in close
contact with patients with suspected or confirmed 2009
H1N1 influenza. Close contact was defined as working
within 6 feet of the patient or entering into a small
enclosed airspace shared with the patient (e.g. average
patient room). The standard precaution for all patient
care was use of non-sterile gloves for any contact with
potentially infectious material, followed by hand hygiene
immediately after glove removal; use of gowns along
with eye protection for any activity that might generate
splashes of respiratory secretions or other infectious
material.
Respiratory protection recommendation, according to
CDC continues to be the use of respiratory protection
that is at least as protective as a fit-tested disposable
N95 respirator for healthcare personnel who are in close
contact with patients with suspected or confirmed 2009
H1N1 influenza. This recommendation applies uniquely
to the special circumstances of the H1N1 pandemic
during the fall and winter of 2009-2010 and CDC will
continue to revisit its guidance as new information
becomes available, within this season if necessary.
The current recommendation is based on the unique
conditions associated with the current pandemic, includ-
ing low levels of population immunity to 2009 H1N1
influenza, availability of vaccination programs well after
the start of the pandemic, susceptibility to infection of
those in the age range of healthcare personnel, increased
risk for complications of influenza in some healthcare
personnel (e.g. pregnant women), and the potential for
healthcare personnel to be exposed to H1N1 influenza
patients because of their occupation [32].
Respiratory evaluation with FVC, FEV1 and DLCO
was determined according to a joint statement based on
the previous statements from the American Thoracic
Society and European Respiratory Society [33]. Patients
were evaluated the day of their discharge and every
three months until six months all follow up were com-
plete for each one. The concept was to evaluate whether
these patients had clinical presentation of adverse effects
of the virus on their respiratory capacity and to establish
the duration of these effects.
Statistical analysis
Analysis was carried out with the use of SPSS statistical
software package (SPSS version 17.01; SPSS, Chicago,
IL, USA). Continuous variables were expressed as mean
± SD or median (with interquartile ranges). For catego-
rical variables, the percentages of patients in each
category were calculated. Unpaired t-test was used in
normally distributed parameters to compare the mean
values between the two groups. A p value of less than
0.05 was considered to indicate statistical significance.
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Mean patient age was 36 years (14-65). The majority of
the confirmed patients hospitalized were Caucasian
male (28/44). All patients were treated immediately with
oseltamivir (75-150 mg every 12 hours). Treatment with
oseltamivir was continued for 4 to 10 days depending
on the individual patient’s clinical condition. In 12/44
patients, empiric antibiotic treatment (azithromycin
+amoxicillin+clavulanic-acid or ceftriaxone+quinolone)
was given upon admission due to suspected secondary
bacterial pneumonia elevated C-reactive protein, WBC
count and local patchy shadowing on x-ray as reported
in previous studies [34-36]. C-reactive protein and WBC
count were elevated in these patients with local patchy
shadowing on radiography (12/44 pts 27.2%).
Patients with radiological evidence of pneumonia were
tested for serum procalcitonin (PCT) (36 patients in
total) and Legionella/Streptococcus pneumoniae urinary
antigens. Pneumonia score index (PSI) was applied and
empirical antibiotic treatment was initiated according
the treating physician’s clinical judgment. Patient’sp r o -
calcitonin test was within normal range (0.05-0.1) in all
patients. Additionally, urine antigen results for Legio-
nella and Streptococcus pneumoniae and blood culture
that were drawn were also negative. The pneumonia
score index was evaluated in these patients and the
range was between class II to IV for 12/44 patients [37].
Coexisting conditions were as follows: asthma 15/44
(34%), chronic obstruction disease 6/44 (13.6%), diabetes
mellitus 8/44 (18.1%), coronary heart disease 10/44
(22.7%), lymphoma 5/44 (11.3%). Median laboratory
values were: C- reactive protein 5.18 mg/dl, white blood
count (WBC) 7.114, urea 26.18 mg/dl, creatinine 0.9
mg/dl, aspartate aminotransferase (AST) 27.09 IU/l, ala-
nine aminotransferase (ALT) 24.48 IU/l. Abnormal liver
function was observed in 7/44 (15.9%). Mean tempera-
t u r ea n do x y g e ns a t u r a t i o nu p o na d m i s s i o nw e r e3 9 . 0 6 °
C and 96.07%, respectively. Median PO2 was 81.23
mmHg. Severe hypoxemia upon admission, defined as
decreased partial pressure of oxygen in blood ≤ 60
mmHg with FiO2 21% [29], was observed in 7/44
patients. There was no thrombocytopenia observed.
Median duration of hospitalisation and fever were 5.39
days and 2.45 days, respectively. Median body-mass
index (BMI) was 30.23 kg/m
2. Obesity (BMI ≥ 30 kg/m
2
[38]) was noted in 11/44 and morbid obesity (BMI ≥ 40
kg/m
2) was noted in 12/44 patients. Patient characteris-
tics are presented in Table 1.
No further pharyngeal or nasopharyngeal swabs were
taken during hospitalization or after treatment. The
criteria for discharge were absence of hypoxemia and
temperature ≤ 37°C for 1 day without antipyretic
treatment [17].
Patient’s respiratory capacity was evaluated with FVC,
FEV1 and DLCO upon discharge and every three
months until six months of observation was completed
for each patient. The evaluation is demonstrated accord-
ing to four categories which the authors selected based
on the same underlying disease of the patients: a)
chronic obstructive pulmonary disease, b) asthma, c) co-
morbidities (diabetes mellitus, coronary heart disease,
and cancer), d) previously healthy patients. Whenever a
patient had both an underlying respiratory disease and
co-morbidity he was selected to be included in a group
according to his major factor affecting his clinical out-
come, preferably his underlying respiratory background.
There was no association between radiographic data and
pulmonary function tests. The mean values for FVC,
FEV1 and DLCO are presented in Figures 1. A signifi-
cant difference was observed between mean values of
FEV1, FVC and DLCO between the evaluations upon
discharge and the sixth month follow up (Table 2).
Discussion
We described a retrospective cohort study of 44 patients
who were hospitalized with the pandemic 2009/10 Influ-
enza A (H1N1) in the University Hospital of Alexan-
droupolis, Thrace from 10
th August 2009 to 15
th
November 2010. So far, there has been no evaluation of
H1N1 respiratory function. The correlation between the
mechanisms and the impact that viruses have on the
respiratory system has been established in previous pub-
lished studies [14-17,28,29,39-44]. As might be antici-
pated, we found a major decreased respiratory capacity
(FEV1 -10.205, FVC -9.909, DLCO -12.409) between the
measurements taken upon discharge and in the six-
month follow-up. This occurred due to the inflamma-
tory effects of the virus through the respiratory tract.
The differentiation of respiratory capacity also varied
between the measurements taken upon discharge and
the three-month follow-up, but it was observed that the
variation was smaller in comparison to the sixth-month
v i s i t ,w h i c hi sp o s s i b l yd u et ot h et i m en e e d e df o rt h e
resolution of the inflammatory effects.
Patients with previously diagnosed respiratory disease
such as COPD and asthma were well controlled on their
treatment. H1N1 induced inflammation and was the
factor that dysregulated their condition. WBC count and
CRP were elevated in patients with suspected bacterial
infection. Hypoxemia was more severe in patients with
opacities on chest x-rays. The mean values in 7/44
patients with abnormal liver functions did not exceed
138 IU/L for ALT and 125 IU/L for AST. These patients
did not present jaundice or other clinical signs of
liver dysfunction. Patients with BMI ≥ 30 kg/m
2 were
20/44, implicating a mild clinical course overall, since
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Upon admission Upon Discharge
Characteristic H1N1(+) Mean Range (±SD) Mean Range (±SD)
Age (years) 36 14-65 (14.7)
Male/Female (n, %) 28/16 (63.6%/36.3%)
Smokers
(male/female) (n, %) 8/28 (28.6%) and 3/16 (18.8%)
Non-Smokers
(male/female) 20/28 (71.4%) and 13/16 (81.3%)
BMI 30.23 20-45 (8.757)
No,pts with obesity (male/female) 7/28 (25%) and 4/16 (25%)
No.pts without obesity (male/female) 21/28 (75%) and 12/16 (75%)
Co-exististing conditions (n, %)
Asthma 15/44 (34%)
COPD 6/44 (13.6%)
IPF 1/44 (2.2%)
Lymphoma 5/44 (11.3%)
Diabetes 8/44 (18.1%)
Coronary Heart Disease 10/44 (22.7%)
Outcomes-days
Duration of fever in hospital under treatment 2.45 1-4 (0.875)
Days of Hospitalization 5.39 3-12 (1.781)
Days under oseltamivir regimen 5.25 4-10 (1.014)
Adverse events (n, %)
Abnormal liver function 7/44 (15.9%)
Nausea, Diarrhea 4.5%
Vomiting 1.4%
Hypoxemia 1/44 (21.2%)
CRP 5.18 0.26-17.38 (5.123) 1.33 0.16-4.53 (1.01)
WBC 7.114 3.340-10.950 (2172.160) 6.806 3340-10950 (2021.6)
Fever 39.06 37-40 (0.834) 37.8 36.3-39.2 (0.77)
CR 0.9 0.5-1.30 (0.17) 0.8 5-1 (0.12)
UR 26.18 11-41 (7.469) 25.11 12-40 (7.127)
SGPT 24.48 10-138 (26.37) 27.80 9-136 (26.719)
SGOT 27.09 14-125 (22.941) 24.14 9-57 (12.22)
Spo2 (FiO2 21%) 96.07 89-99 (2.3) 96.98 94-99 (1.248)
PO2 (FiO221%) 81.23 53-113 (14.586) 87.66 67-113 (12.473)
Abnormalities on chest radiograph (n, %)
Local patchy shadowing 8/44 (18.1%) 6/44 (13.6%)
Ground-glass opacities 3/44 (6.8%) 2/44 (4.5%)
Interstitial abnormality 1/44 (2.2%) 1/44 (2.2%)
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The laboratory findings were not correlated with the
respiratory functions, based on the fact that patients
upon exacerbation or with opacities on chest x-ray
would present a severe deterioration of their respiratory
capacity. None of the patients had been previously vac-
cinated, but all patients received oseltamivir immediately
on hospitalization and antibiotics upon suspicion of bac-
terial respiratory infection preventing an escalation of
the inflammation and infection.
The mechanisms of H1N1-induced respiratory effects
have received considerable attention [39-44]. Recent stu-
dies have shown that the high mortality rate of avian
influenza virus infections is a consequence of an overac-
tive inflammatory response and the severity of infection
is closely related with virus-induced cytokine dysregula-
tion. The most important feature of influenza A
immune-pathogenesis is the appearance of “cytokine
storm”, which is characterized by the extreme
production and secretion of numerous pro-inflammatory
cytokines. This is responsible for the development of
lethal clinical symptoms, such as massive pulmonary
edema, acute bronchopneumonia, alveolar hemorrhage,
reactive hemophagocytosis, and acute respiratory
distress syndrome, associated with necrosis and tissue
destruction. Numerous in vitro, in vivo and clinical
studies have pointed out that A/H5N1 viruses are very
strong inducers of various cytokines and chemokines
(Tumor Necrosis Factor [TNF]-alpha, Interferon [IFN]-
gamma, IFN-alpha/beta, Interleukin [IL]-6, IL-1, MIP
[Macrophage Inflammatory Protein] -1, MIG [Monokine
Induced by IFN-gamma], IP [Interferon-gamma-Induci-
ble Protein]-10, MCP [Monocyte Chemoattractant
Protein]-1, RANTES [Regulated on Activation Normal
T-cell Expressed and Secreted], IL-8), in both humans
and animals. The major cells implicated in the cytokine
storm are macrophages and CD8+ T-lymphocytes, while
the primary contributor cytokines are TNF-alpha, IL-6
Figure 1 Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 sec (FEV1), Carbon Monoxide Diffusing Capacity (DLCO) mean
values for patients with Chronic Obstructive Pulmonary Disease (COPD), patients with Asthma, patients without any respiratory
disease (NO RD), patients with co-morbidities.
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some viral genes (NS1, PB2, HA and NA) are responsi-
ble for the “cytokine storm”,b yi n c r e a s i n gt h ev i r a l
replication rate, expending the tissue tropism, as well as
facilitating the systemic invasion and the development
of resistance against the host antiviral response. Glu92
and Ala149 mutations and carboxyl-terminal ESEV/
EPEV motif of NS1 protein have been implicated as
determinants of virulence for A/H5N1 strains. In addi-
tion, Lys627 mutation in PB2 protein, polybasic aminoa-
cid mutations in the cleavage region of hemagglutinin
(HA) polyprotein, and glycosylation and sialyzation
mutations in HA and neuraminidase (NA) proteins were
found to enhance the immune-mediated pathology of
highly virulent A strains [40-45]. Furthermore, in a pre-
liminary analysis of macrophage gene expression data
based on published studies, 64 genes in H1N1-infected
cells showed at least 1.5-fold difference in expression
level compared to mock infected cells in at least one
time point [43]. Impressively, as many as 60 genes were
thereby upregulated [43].
Given these important inflammatory processes, it is
important to attempt patient prophylaxis. Several anti-
viral agents were tested both in vitro and/or in vivo and
presented results implicating that the early use of such
agents suppress the inflammation apart from being a
therapy [43-49] Antibiotics especially macrolides, which
are well known for their anti-inflammatory and immu-
nomodulatory properties were also tested. Clarithromy-
cin inhibits the middle to late stage of the influenza
virus replication cycle, resulting in inhibition of progeny
virus production from the infected cells. Macrolides
could mediate this effect by inhibiting intracellular
hemagglutinin HA0 proteolysis. The inhibitory effect on
influenza virus replication of macrolides has been
known since the 80s [50-54]. N-acetylcysteine (NAC) is
a thiol-containing compound which non-enzymatically
interacts and detoxifies reactive electrophiles and free
radicals. NAC has already been shown to effectively pro-
tect human bronchial fibroblasts against the toxic effects
of tobacco smoke condensates and the isolated perfused
lung against the glutathione (GSH)-depleting effect of
tobacco smoke. NAC has also been demonstrated to
reduce the reactive oxygen intermediate hydrogen
peroxide (H2O2) and to confer protection from the toxic
effects of H2O2. In vivo studies, however, have demon-
strated that orally administered NAC has very low bioa-
vailability due to its rapid metabolism mainly to GSH
but also other metabolites. Thus, even though NAC is
very effective in protecting cells of different origins from
the toxicity of reactive components in tobacco smoke
and reactive oxygen species, a direct scavenging effect
by NAC in vivo, does not seem likely. This holds espe-
cially true for oral administration. A more relevant
mechanism in vivo for any protective effect of NAC
may be attributable to its activity as a precursor of GSH,
thereby facilitating its biosynthesis. GSH will then serve
as the protective agent and detoxify reactive species
both enzymatically and non-enzymatically [55,56].
Finally, the efficacy of vaccination for H1N1 has been
documented by assessing antibody formation in the
vaccinated elderly subjects from the 2009 pandemic in
contrast to the younger ones who were not vaccinated.
Nonetheless, antibodies from older subjects previous
encounter with pandemic influenza A strains may be a
confounding factor [57].
This study has a number of limitations. First, our
patient series was small, but it should be borne in mind
that since these H1N1 positive patients represent a
population of 350.000 residents. Furthermore, diagnostic
tests with procalcitonine, urine antigen and blood cul-
tures were given only upon suspicion of an infection.
The respiratory capacity tests represented a small num-
ber of patients in each group, and so no correlations
could be preformed between the four subgroups. In
addition, the baseline condition of each patient was not
evaluated; this was either because they did not have a
respiratory underlying condition or because they were
patients that admitted in our hospital for the first time.
Conclusions
Respiratory capacity differed between categories of
patients at least for the first three months of observa-
tion, probably due to the inflammatory factors that are
released with the influenza A (H1N1) infection and
underlying disease. Importantly, the respiratory
Table 2 Statistical findings as mean values between
follow ups.
DLCO 1DLCO 76.07 -6.750 .000
2DLCO 82.82
1DLCO 76.07 -12.409 .000
3DLCO 88.48
2DLCO 82.82 -5.659 .000
3DLCO 88.48
FEV1 1FEV1 76.18 -8.659 .000
2FEV1 84.84
1FEV1 76.18 -10.205 .000
3FEV1 86.39
2FEV1 84.84 -1.545 .001
3FEV1 86.39
FVC 1FVC 78.52 -8.318 .000
2FVC 86.84
1FVC 78.52 -9.909 .000
3FVC 88.43
2FVC 86.84 -1.591 .000
3FVC 88.43
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the fact that respiratory capacity remained stable
between the second and third measurement. Several
treatment modalities can be administered to confer
protection and suppress the inflammation. Vaccination
and early treatment with antiviral agents represent the
mainstay of management.
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